Centaurus Financial’s CRISPR Therapeutics CRSP Stock Holding History

Centaurus Financial’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,545	Closed	-$117K	–	908
2021 Q4	$117K	Sell	1,545 -500	-24%	-$43.7K	0.01%	843
2021 Q3	$229K	Buy	2,045 +200	+11%	+$25.1K	0.02%	614
2021 Q2	$299K	Sell	1,845 -200	-10%	-$24.3K	0.03%	569
2021 Q1	$249K	Buy	2,045 +492	+32%	+$74.3K	0.02%	547
2020 Q4	$238K	Buy	+1,553	New	+$184K	0.03%	513
2018 Q3	–	Sell	-281	Closed	-$17K	–	825
2018 Q2	$17K	Buy	+281	New	+$16K	﹤0.01%	1336

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Centaurus Financial's CRSP Position: Q1 2022 in Review

Centaurus Financial sold out of CRISPR Therapeutics (CRSP) in Q1 2022, closing a stake of 1,545 shares — an estimated $117K sold.

Centaurus Financial first reported a position in CRSP in Q2 2018 and held it in 6 quarters. The position peaked at $299K in Q2 2021. 447 funds tracked by Wall St. Rank hold CRSP as of Q1 2022.

Centaurus Financial reported no remaining CRISPR Therapeutics position as of Q1 2022 after selling out during the quarter.
Centaurus Financial sold 1,545 CRISPR Therapeutics shares in Q1 2022, an estimated $117K.
Centaurus Financial first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 6 quarters.
Centaurus Financial's CRISPR Therapeutics position peaked at $299K in Q2 2021.
447 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2022.

Based on Centaurus Financial's 13F filing for Q1 2022, filed 13 May 2022.